Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability, describe the
dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) (or the
highest protocol-defined dose level in the absence of establishing an MTD) of ibrutinib in
combination with pembrolizumab in participants with advanced, refractory colorectal cancers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute